BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Germano D, Tinessa V, Barletta E, Cannella L, Daniele B. Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib. Drugs Aging 2013;30:887-92. [PMID: 24097332 DOI: 10.1007/s40266-013-0124-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Wickersham KE, Crothers M, Puth D, Weiss MN, Powell K, Resnick B. Targeted therapy use in adults with cancer ≥85 years of age. Geriatr Nurs 2019;40:63-6. [PMID: 30327159 DOI: 10.1016/j.gerinurse.2018.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 de Stefano G, Iodice V, Farella N. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report. J Gastrointest Cancer 2015;46:430-3. [PMID: 25894635 DOI: 10.1007/s12029-015-9720-5] [Reference Citation Analysis]
3 Ziogas DC, Papadatos-pastos D, Thillai K, Korantzis I, Chowdhury R, Suddle A, O’grady J, Al-khadimi G, Allen N, Heaton N, Ross PJ, Sarker D. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. European Journal of Gastroenterology & Hepatology 2017;29:48-55. [DOI: 10.1097/meg.0000000000000739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
4 Güiza FM, Duarte YB, Mendez-sanchez SC, Bohórquez ARR. Synthesis and in vitro evaluation of substituted tetrahydroquinoline-isoxazole hybrids as anticancer agents. Med Chem Res 2019;28:1182-96. [DOI: 10.1007/s00044-019-02363-z] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
5 Ye S, Zhao XY, Hu XG, Li T, Xu QR, Yang HM, Huang DS, Yang L. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma. Oncol Rep 2017;37:2215-26. [PMID: 28350084 DOI: 10.3892/or.2017.5494] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
6 Edeline J, Crouzet L, Le Sourd S, Larible C, Brunot A, Le Roy F, Cattenoz C, Latournerie M, Gédouin D, Guillygomarc'h A, Boucher E. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. Cancer Chemother Pharmacol 2015;75:215-9. [PMID: 25477009 DOI: 10.1007/s00280-014-2645-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
7 Hajiev S, Allara E, Motedayеn Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. Br J Cancer 2021;124:407-13. [PMID: 33071284 DOI: 10.1038/s41416-020-01116-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, Melisi D, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Bicciato S, Blazar BR, Sahin U, Murray PJ, Bronte V. Induction of immunosuppressive functions and NF-κB by FLIP in monocytes. Nat Commun 2018;9:5193. [PMID: 30518925 DOI: 10.1038/s41467-018-07654-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]